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Read alignment and variant calling in relapsing cases
Read alignment and variant calling were performed following best practices established at the Broad Institute. Specifically, data demultiplexing and initial quality control were performed using Picard (http://picard.sourceforge.net). After demultiplexing, high-quality (pass-filter, PF) reads were aligned to human reference genome hg19/NCBI37 using BWA version 0.5.9. Prior to somatic mutation calling, aligned BAM files were processed using the GATK 2.4-9 software 2, 3 to mark likely PCR duplicates, to realign reads around indels and to recalibrate base quality scores based on common variation. Somatic point mutations were called using MuTect v1.1.4 4 with COSMIC v54 as reference database. Somatic indel calling was performed using IndelGenotyper2 (http://www.broadinstitute.org/cancer/cga/indelocator). For targeted sequencing, mutation calling was restricted to targeted regions (= coding exons plus splice sites) to reduce the number of spurious detections in non-targeted regions due to insufficient sequencing depth. Alignments in recurrently mutated genes were also inspected manually, which led to the identification of 13 additional somatic mutations falsely rejected by MuTect (six in CREBBP, three in NRAS, two in KRAS, one in PTPN11, and one in TP53).
Variant annotation
Variant annotation was performed using SnpEff version 3.3h. for SIFT and SiPhy we considered variants deleterious if they had a score <0.05 and ≥12,
respectively. In addition, we considered mutations impacting extremely well conserved nucleotides (SiPhy score >20) as deleterious, regardless of PolyPhen2 and SIFT predictions.
Post-calling variant filtering
Following variant calling and annotation, somatic point mutations and indels were further filtered to reduce false-positives. Identified indels were subjected to additional filtering, because manual inspection revealed many questionable calls in the raw output of IndelGenotyper2. Called indels were rejected if (a) the total read depth in tumor was <10x (= low coverage filter); (b) the fraction of reads supporting the consensus indel among all reads supporting any indel was below 70% (= low consensus filter); (c) the indel was not supported by reads from both strands (= strand bias filter); (d) indel supporting reads had a higher fraction of mismatching bases than reads supporting the reference allele (= misalignment filter); or (e) the average mapping quality of consensus indel-supporting reads was below 40 (= mapping quality filter).
Post-calling filtered variants were removed from all downstream analyses.
Variant calling in non-relapsing cases
For non-relapsing cases, only diagnostic samples without matched remission were sequenced, which necessitated a different variant calling strategy. Reads were first aligned with BWA and processed with GATK as described previously. SAMtools (version 0. Table S8 ).
Pathway analysis
Pathway analysis was performed with Genome MuSiC version 0.4 15 Enriched gene sets, identified at each leukemia occasion (i.e. at diagnosis and relapse) and by each analysis (i.e. including and excluding RTK/RAS pathway/CREBBP genes), are provided in Supplemental Table S3 . The 144 gene sets, significantly enriched at relapse and excluding RTK/RAS pathway/CREBBP genes, were clustered to produce Supplemental Figure S4 , using the following procedure. First, a binary gene-pathway matrix was constructed, with rows representing mutated genes and columns representing significantly enriched pathways (12 gene sets from MSigDB belonging to categories 'c1_positional' and 'c3_motif' were excluded in this step). Presence and absence of a gene in a pathway was encoded with 1 and 0, respectively. The binary matrix was then clustered independently in both dimensions with R functions 'dist' (distance measure 'binary') and 'hclust'
(agglomeration method 'average'), resulting in a matrix in which pathways sharing the same genes and genes sharing the same pathways are grouped together. The clustered matrix was color-coded (1=black, 0=white) and plotted alongside hierarchical trees for visual interpretation.
Functional groups identified in Supplemental Figure S4 were then used as scaffold to manually construct an extended gene-case mutation matrix containing both recurrently and non-recurrently mutated genes (Supplemental Figure S5 ). Recurrently mutated genes were put at the top and non-recurrently genes were put into their corresponding functional groups as identified by pathway analysis. The matrix was manually augmented by genes carrying missense mutations not predicted to be deleterious, which were assigned to functional groups based on manual review of GeneCards annotations (http://www.genecards.org).
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Identification of hot-spot mutations in RTK/Ras pathway genes
Mutational hotspots in KRAS, NRAS, and PTPN11 genes were identified by first searching the COSMIC database for genomic positions impacted most frequently by somatic mutations.
This search identified seven clear mutational hotspots for both KRAS and NRAS and 17 for PTPN11. Using a custom R script, BAM files from targeted sequencing were then inspected at these 31 hotspot positions to find reads supporting non-reference alleles. A mutation was called if (a) it was supported by at least two reads from both strands and (b) the mean base quality of the non-reference allele was at least 22 on both strands. Because FLT3 mutations were much less clustered than KRAS, NRAS, and PTPN11 mutations, we augmented KRAS, NRAS, and PTPN11 hotspot mutations with FLT3 mutations previously identified by MuTect.
All RTK/Ras pathway mutations identified by this procedure are provided in Supplemental   Table S7 . In a control experiment, we searched 82 remission samples for non-reference Ras pathway alleles using the exact same procedure, but did not call any mutation. This suggests that the false-positive rate of the mutation hotspot caller is very low, at least below one error per 2 500 investigated hotspots.
Supplementary Results
Transition versus transversion ratio
The average transition/transversion (Ti/Tv) ratio of mutations at diagnosis and relapse was similar (1.6 and 1.4; P=0.14) and thus not indicative of a genotoxic drug effect or mutator phenotype.
Frequency and description of mutated genes from targeted sequencing
Recurrent targets of sequence mutations were RTK/Ras pathway genes (63%), CREBBP 
Altered pathways at diagnosis and relapse
Pathway analyses revealed enrichment of deleterious mutations in genes implicated in transcription, cell signaling, cytoskeleton, cell cycle, development or differentiation (P<1e-6) (Supplemental Table S3 and Figure S4 ). Together with pathways responsible for drug resistance and hypoxia regulation, they were significantly more common at relapse. When we performed the analyses without CREBBP and RTK/Ras, the central hubs in many of these pathways, 53, 54 the most prominent of the remaining ones at diagnosis was MSigDB gene set prostaglandin E2 DN (P=2.4e-8), while at relapse all other pathways remained statistically significant. These findings may suggest that other relapse-specific mutations in these pathways either substitute for mutated RTK/Ras and/or CREBBP genes, or when they co-occur, even synergize in their function and progression towards relapse (Supplemental Figure S5 ).
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